Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, ra...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Future Oncol
Glavni autori: Roboz, Gail J, Montesinos, Pau, Selleslag, Dominik, Wei, Andrew, Jang, Jun-Ho, Falantes, Jose, Voso, Maria T, Sayar, Hamid, Porkka, Kimmo, Marlton, Paula, Almeida, Antonio, Mohan, Sanjay, Ravandi, Farhad, Garcia-Manero, Guillermo, Skikne, Barry, Kantarjian, Hagop
Format: Artigo
Jezik:Inglês
Izdano: Future Medicine Ltd 2016
Teme:
Clinical Trial Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684733/
https://ncbi.nlm.nih.gov/pubmed/26785287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.326
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items